Key Drivers
- Cash-Rich Balance
- No Revenue
- Ongoing Burn
AIAI Summary
ANRO should now be viewed as a cash-backed, single-catalyst biotech where ALTO-207 is the main upside driver, but with ALTO-100's failure, ongoing burn, and dilution risk making the stock highly binary and dependent on near-term clinical proof.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash-Rich Balance
- •No Revenue
- •Ongoing Burn
ANRO has a very strong cash-rich, low-debt balance sheet, but the absence of revenue, ongoing losses, and continued cash burn make its financial strength unsustainable without a turnaround.
Price Behavior
Key Price Behavior Insights:
- •Breakout strength
- •Higher-highs trend
- •Stretch risk
ANRO is in a clear short-term uptrend after breaking above $28.60-$29.20, but with price near last month's high, momentum looks stretched and a pullback below $29.20 would weaken the breakout.
Broke above the late-July ceiling around $28.60-$29.20 and rallied toward last month's high
Sentiment & News
Key News Insights:
- •Strong analyst support
- •ALTO-207 focus
- •Mixed pipeline
Analyst sentiment on Alto Neuroscience remains constructive, with strong support centered on ALTO-207 despite mixed pipeline results and ALTO-100's setback.
The news is modestly positive for Alto Neuroscience as ALTO-207 momentum and analyst backing help offset disappointment from prior pipeline failure
Similar Companies in Healthcare
Other companies in the same sector with AI ratings